The Stockholm3 test is a multivariable biomarker and clinical predictive model that decreases the number of biopsies needed to find International Society of Urological Pathology grade group ≥2 (GG ≥2) prostate cancer by 32% when maintaining the same sensitivity as a PSA cutoff of 3 ng/ml [9]. This evidence concerns the gene KLK3 and prostate carcinoma.